0%
Print report
Variant interpretation report

PRF1 c.626A>C, p.Gln209Pro

NM_001083116.3:c.626A>C NP_001076585.1:p.(Gln209Pro) Missense · exon 3 View identifiers
Classification
Uncertain significance

Variant description:

The PRF1 NM_001083116.3:c.626A>C (NP_001076585.1:p.(Gln209Pro)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About PRF1

PRF1 encodes perforin-1, an immune protein that forms pores in target-cell membranes so immune cells can release granzymes and destroy infected or abnormal cells. Changes in PRF1 are associated with familial hemophagocytic lymphohistiocytosis type 2, a severe inherited immune disorder, as well as autoimmune lymphoproliferative syndrome, aplastic anemia, diabetes, multiple sclerosis, and some lymphomas. Its cancer relevance is mainly through these associations with lymphoma and immune-system dysfunction; no broader established cancer role is described.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 2 Benign evidence criteria: 0
Pathogenic criteria applied · 2
PS4Strong
PS4 · strong

Met: one carrier among 1892 affected patients versus 31 among 589971 matched controls gives OR 10.06 (95% CI 1.37–73.76), exceeding the OR >5.0 threshold with CI excluding 1.

PM2Supporting
PM2 · supporting

Met at supporting strength: gnomAD v4.1 grpmax FAF is 1.883e-05, below the <=0.0001 PM2 threshold, with zero homozygotes.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PS4 (strong) plus PM2 (supporting) do not satisfy any generic ACMG/AMP pathogenic, likely pathogenic, benign, or likely benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
31 / 1,613,994 alleles

gnomAD v4.1: 31 / 1,613,994 alleles. Recorded AF 1.9207e-05. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.20556e-05; MAF= 0.00121%, 3/248848 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 6.18276e-05; MAF= 0.00618%, 1/16174 alleles, homozygotes = 0); grpmax FAF= 2.98e-06.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.420 recorded score

Recorded REVEL score: 0.420. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
2 reported laboratory submissions

1 Uncertain significance · 1 Pathogenic. ClinVar API review status: criteria provided, conflicting classifications.

Context only ClinVar ↗
No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 8 not met · 14 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

None of PS2, PM6, PP1, or BS4 can be assessed because the available evidence lacks case-specific parental, pedigree, phenotype, and segregation data.

Only PS4, PP4, PP5, BP5, and BP6 were adjudicated.

PS4 was assessed from the exact-variant affected-patient count in PMID:32542393 against matched-ancestry gnomAD v4.1 controls, with the OR and 95% CI computed from the reported counts.

PP5 and BP6 were restricted to exact-variant ClinVar expert-panel classifications; none were present.

Met · 2

PS4 StrongACMG_2015Met: one carrier among 1892 affected patients versus 31 among 589971 matched controls gives OR 10.06 (95% CI 1.37–73.76), exceeding the OR >5.0 threshold with CI excluding 1. Details ▾Hide ▴
Reasoning

PS4 is met under the generic ACMG/AMP rule. Gadoury-Levesque et al. reported the exact variant NM_001083116.3:c.626A>C (p.Gln209Pro) in 1 of 1892 patients evaluated for suspected genetic HLH; the patient was European-American and carried the variant heterozygously. Using matched European non-Finnish gnomAD v4.1 controls, the variant was present in 31 of 1,179,942 alleles with no homozygotes, corresponding to approximately 31 of 589,971 individuals. Treating the affected-patient and control carrier counts as a case-control comparison, the odds ratio is 10.06 with an approximate 95% CI of 1.37-73.76, computed from the reported counts; the CI excludes 1.0 and OR >5.0. The other literature-pass PS4 candidate, PMID:26450956, was checked against its full text and does not mention this exact variant or provide a case-control comparison.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • Gadoury-Levesque et al., Table 1, patient 27: European-American female with PRF1 c.626A>C (p.Gln209Pro), heterozygous, in a cohort of 1892 patients with suspected genetic HLH disorders.
  • Computed case-control comparison from reported counts: affected carriers 1/1892; matched-ancestry gnomAD v4.1 NFE controls 31/589971 individuals (31/1179942 alleles, no homozygotes); OR=10.06 and approximate Wald 95% CI=1.37-73.76.
  • The OR and 95% CI were computed from the case and matched-ancestry control counts; the CI does not include 1.0.
  • PMID:26450956 was checked in full text; it concerns flow-cytometric perforin screening but does not mention c.626A>C or p.Gln209Pro and supplies no case-control comparison for this variant.
Sources
PM2 SupportingACMGMet at supporting strength: gnomAD v4.1 grpmax FAF is 1.883e-05, below the <=0.0001 PM2 threshold, with zero homozygotes. Details ▾Hide ▴
Reasoning

PM2 is met at supporting strength under the supplied generic SVI threshold. The default all-comers gnomAD v4.1 filtering grpmax FAF is 1.883e-05, below the <=0.0001 PM2 threshold; the variant is present at 31/1,613,994 alleles with zero homozygotes. Supporting data are concordant in gnomAD v2.1 all-comers (3/248,848 alleles; grpmax FAF=2.98e-06) and gnomAD v2.1 non-cancer exomes (3/234,374 alleles; AF=1.28001e-05; grpmax FAF=3.3e-06). Under the generic rules, no VCEP-specific non-cancer or exome-only source requirement overrides the all-comers default.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium. ... PM2 (supporting): <= 0.0001 — SVI recommendation to downgrade PM2 to Supporting (ClinGen SVI 2020) (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: 31/1,613,994 alleles, AF=1.9207e-05, zero homozygotes, filtering grpmax FAF=1.883e-05.
  • gnomAD v2.1 all-comers: 3/248,848 alleles, AF=1.20556e-05, zero homozygotes, filtering grpmax FAF=2.98e-06.
  • gnomAD v2.1 non-cancer exomes: 3/234,374 alleles, AF=1.28001e-05, zero homozygotes, filtering grpmax FAF=3.3e-06.
  • The case is governed by generic ACMG/AMP rules because no VCEP covers PRF1; therefore the all-comers gnomAD v4.1 entry remains the default, with the non-cancer exome result as concordant corroboration.
  • Generic calibration supplied for this case: PM2 supporting threshold <=0.0001, identified as the SVI recommendation to downgrade PM2 to Supporting (ClinGen SVI 2020; PMID:25741868).
Sources

Not met · 8 · evaluated, threshold not reached

PP3 ACMGNot met: the missense REVEL score is 0.42, below the generic supporting PP3 threshold of 0.644. Details ▾Hide ▴
Reasoning

PP3 applies here through the missense path only, so REVEL is the governing predictor and SpliceAI is excluded from this criterion. NM_001083116.3:c.626A>C in PRF1 is a missense variant producing p.(Gln209Pro), and its REVEL score is 0.42. This is below the generic ClinGen SVI supporting PP3 threshold of >= 0.644, so PP3 is not met. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)...Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant....PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001083116.3:c.626A>C, p.(Gln209Pro).
  • Applicable predictor path: missense variants use REVEL only; the SpliceAI score is not evidence for PP3/BP4 in this situation.
  • Local REVEL lookup reports a score of 0.42 for this variant.
  • Generic ClinGen SVI REVEL calibration: PP3 supporting requires >= 0.644 (Pejaver et al. 2022, Am J Hum Genet, PMID:36413997).
  • BayesDel is not used because no generic ACMG-strength calibration is established for PP3/BP4.
Sources
revel
PP4 ACMG_2015Not met: HLH is genetically heterogeneous across 15 genes in the source cohort, so the phenotype is not highly specific for a single genetic etiology. Details ▾Hide ▴
Reasoning

The exact-variant report is in a suspected HLH cohort, but HLH is genetically heterogeneous rather than a phenotype with a single genetic etiology. The study evaluated 15 HLH-associated genes and identified multiple genetic causes, so the available phenotype information does not satisfy the required high specificity for PRF1-related disease.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • The study abstract states that 1892 suspected genetic HLH patients were analyzed across 15 HLH-associated genes and that other possible etiologies should be investigated; this is not a phenotype specific to PRF1.
  • The exact variant was reported in a patient with absent perforin expression, but that finding does not establish a phenotype highly specific for a single genetic etiology.
Sources
PP5 ACMG_2015Not met: ClinVar has one single-laboratory Pathogenic assertion but zero expert-panel submissions and conflicting overall classifications. Details ▾Hide ▴
Reasoning

PP5 is not met. ClinVar contains one Pathogenic submission from a single clinical laboratory, one conflicting Uncertain significance submission, and zero expert-panel submissions. A single laboratory assertion and the aggregate conflicting ClinVar record do not satisfy the required exact-variant expert-panel source condition.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 666080 exact-match record: one Pathogenic submission from Labcorp with review status criteria provided, single submitter; one conflicting Uncertain significance submission from GeneDx; expert-panel submissions=0.
  • The Pathogenic submission is an ordinary clinical-laboratory assertion, not an exact-variant expert-panel classification.
Sources
BA1 ACMGNot met: gnomAD v4.1 grpmax FAF is 1.883e-05, far below the >=0.05 BA1 stand-alone threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. The decisive filtering frequency is the gnomAD v4.1 grpmax FAF of 1.883e-05, based on the European (non-Finnish) group with 1,179,942 observed alleles, which is far below the generic stand-alone threshold of >=0.05. The gnomAD v2.1 all-comers grpmax FAF was 2.98e-06; the non-cancer exome subset had AF 1.28001e-05 and grpmax FAF 3.3e-06. No population frequency approaches 5%, and the available ClinVar record is conflicting rather than a concordant pathogenic consensus that would require additional caution about a high-frequency disease-associated allele.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium. ... BA1 (stand-alone): >= 0.05 — ACMG/AMP 2015 stand-alone benign allele frequency (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: 31/1,613,994 alleles, AF 1.9207e-05, homozygotes 0; filtering grpmax FAF=1.883e-05, with the highest observed subgroup AF 2.62725e-05 in European (non-Finnish) individuals across 1,179,942 alleles.
  • gnomAD v2.1 all-comers: 3/248,848 alleles, AF 1.20556e-05, homozygotes 0; filtering grpmax FAF=2.98e-06.
  • gnomAD v2.1 non-cancer exomes: 3/234,374 alleles, AF 1.28001e-05, homozygotes 0; filtering grpmax FAF=3.3e-06.
  • Generic calibration supplied for this case: BA1 stand-alone threshold >=0.05, attributed to ACMG/AMP 2015 (PMID:25741868).
Sources
BS1 ACMGNot met: gnomAD v4.1 filtering grpmax FAF is 1.883e-05, below the generic >=0.01 BS1 frequency threshold. Details ▾Hide ▴
Reasoning

BS1 is not met on the available population data. The required filtering frequency is gnomAD v4.1 grpmax FAF=1.883e-05, well below the generic default threshold of >=0.01, and the observed subgroup point estimate (2.62725e-05) is also far below that threshold. The gnomAD v2.1 all-comers grpmax FAF was 2.98e-06 and the non-cancer exome subset grpmax FAF was 3.3e-06. Because the frequency is orders of magnitude below 1%, no maximum-credible-frequency calculation is needed to establish that this variant is not too common for the disorder on the supplied data; there is no elevated ancestry-specific frequency requiring a penetrance or founder-effect exception.

Rule
Allele frequency is greater than expected for the disorder. ... BS1 (strong): >= 0.01 — Generic SVI default; per-gene derivation preferred (Whiffin et al. 2017) (PMID:28518168)
Evidence considered
  • gnomAD v4.1 all-comers: filtering grpmax FAF=1.883e-05; highest observed subgroup AF=2.62725e-05 in European (non-Finnish) individuals with 1,179,942 observed alleles.
  • gnomAD v2.1 all-comers: filtering grpmax FAF=2.98e-06; non-cancer exome subset: filtering grpmax FAF=3.3e-06.
  • The elevated-frequency ancestry exception is not relevant because the maximum observed subgroup AF is only 2.62725e-05, not near the 0.01 default.
  • Generic calibration supplied for this case: BS1 default threshold >=0.01; per-gene derivation is preferred under Whiffin et al. 2017 (PMID:28518168).
Sources
BP4 ACMGNot met: the missense REVEL score is 0.42, above the generic supporting BP4 threshold of 0.29 and therefore gray-zone. Details ▾Hide ▴
Reasoning

BP4 applies here through the missense path only, so REVEL is the governing predictor and SpliceAI is excluded from this criterion. NM_001083116.3:c.626A>C in PRF1 is a missense variant producing p.(Gln209Pro), and its REVEL score is 0.42. The score is above the generic supporting BP4 threshold of <= 0.29 and therefore lies outside the BP4-supporting range; the gray-zone result does not permit substituting the SpliceAI max delta of 0.05. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)...Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant....BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001083116.3:c.626A>C, p.(Gln209Pro).
  • Applicable predictor path: missense variants use REVEL only; the SpliceAI score is not evidence for PP3/BP4 in this situation.
  • Local REVEL lookup reports a score of 0.42 for this variant, which is above the BP4 supporting cutoff and remains indeterminate for benign computational evidence.
  • Generic ClinGen SVI REVEL calibration: BP4 supporting requires <= 0.29 (Pejaver et al. 2022, Am J Hum Genet, PMID:36413997).
  • SpliceAI max delta is 0.05, but it is not used because this is a missense variant and the governing path is REVEL only.
  • BayesDel is not used because no generic ACMG-strength calibration is established for PP3/BP4.
Sources
revel
BP5 ACMG_2015Not met: the reported second variant is also in PRF1, and no alternate molecular basis for the patient's disease is documented. Details ▾Hide ▴
Reasoning

BP5 is not met. The exact-variant report shows c.626A>C together with another PRF1 variant in the same patient, not an alternate molecular basis for disease. No pathogenic variant in a different disease gene or other independent alternate molecular diagnosis is reported for this case.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • Gadoury-Levesque et al., Table 1, patient 27: PRF1 c.227G>A (p.Cys76Tyr) and PRF1 c.626A>C (p.Gln209Pro) are both listed; this is not an alternate molecular basis in another disease gene.
  • No alternate molecular diagnosis is reported for the exact-variant case.
Sources
BP6 ACMG_2015Not met: ClinVar provides no exact-variant expert-panel benign or likely benign classification and reports zero expert-panel submissions. Details ▾Hide ▴
Reasoning

BP6 is not met. The exact-variant ClinVar record contains no benign or likely benign expert-panel classification; it contains one Pathogenic single-laboratory submission and one Uncertain significance submission, with zero expert-panel submissions.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 666080 exact-match record: no Benign or Likely benign expert-panel assertion; expert-panel submissions=0, with conflicting Pathogenic and Uncertain significance laboratory submissions.
Sources

Not assessed · 14 · no assessment recorded

PS1 ACMG_2015Not assessed: no validated pathogenic comparator with the same amino-acid change, independent of the nucleotide change, was available for PRF1 p.Gln209Pro. Details ▾Hide ▴
Reasoning

The variant is PRF1 p.Gln209Pro. The available ClinVar record is an exact match to this variant and contains one pathogenic single-submitter classification, but it does not establish a previously established pathogenic variant with the same amino-acid change caused by a different nucleotide change. No validated same-amino-acid comparator was identified in the supplied evidence, and the available paper-extracts object contains no extracted literature findings.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinVar variation 666080 identifies the exact variant as NM_001083116.3(PRF1):c.626A>C (p.Gln209Pro) and reports conflicting classifications: one pathogenic and one uncertain-significance submission; this is not evidence of a different-nucleotide same-amino-acid comparator.
  • paper_extracts.json is empty, so no extracted paper finding establishes a same-amino-acid pathogenic comparator.
Still missing
  • A validated pathogenic PRF1 variant producing p.Gln209Pro through a different nucleotide change is needed.
  • The ClinVar pathogenic submission is for the exact c.626A>C p.Gln209Pro variant and cannot by itself establish PS1.
Sources
PS2 ACMG_2015Not assessed: no documented proband disease with confirmed maternity and paternity, de novo status, and absence of family history. Details ▾Hide ▴
Reasoning

No case-level evidence documents that NM_001083116.3:c.626A>C occurred de novo, confirms both maternity and paternity, establishes the proband's disease, or excludes a family history. Therefore PS2 cannot be assessed.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The available case evidence documents the variant and general PRF1/FHLH literature but contains no proband-parent trio results or family-history assessment.
Still missing
  • Proband-level disease phenotype and diagnosis are not documented.
  • Parental testing results confirming maternity and paternity are not documented.
  • Variant presence or absence in both biological parents is not documented.
  • Family history is not documented.
PS3 ACMG_2015Not assessed: no variant-specific validated functional assay or assay result for PRF1 c.626A>C (p.Gln209Pro) was available. Details ▾Hide ▴
Reasoning

The variant is NM_001083116.3:c.626A>C (PRF1 p.Gln209Pro). The available case evidence does not provide a variant-specific in vitro or in vivo functional result, assay controls, biological-effect measurement, or evidence that an assay for this variant is validated, reproducible, and robust in a clinical diagnostic laboratory setting. The cited publications were screened, but the available records do not identify this exact variant as having functional assay data. Therefore, the PS3 requirement for well-established functional evidence supportive of a damaging effect cannot be adjudicated from the available evidence.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • The case evidence identifies NM_001083116.3:c.626A>C as PRF1 p.Gln209Pro but contains no variant-specific functional assay result.
  • PMID:26450956 was screened by title and case-evidence metadata; the available record concerns flow-cytometric perforin screening but does not document a functional result for p.Gln209Pro.
  • PMID:32542393 was screened by abstract and case-evidence metadata; the available record describes a sequencing cohort and does not document a functional result for p.Gln209Pro.
  • PMID:28492532 was screened as a general ACMG/AMP criteria-refinement paper and does not provide variant-specific functional evidence.
Still missing
  • Variant-specific in vitro or in vivo functional assay result
  • Assay controls and biological relevance
  • Validation, reproducibility, and robustness of the assay
PM1 ACMG_2015Not assessed: residue 209 lacks supplied evidence of a critical functional domain or mutational hotspot without benign variation. Details ▾Hide ▴
Reasoning

PRF1 p.Gln209Pro is not reported in the supplied Cancer Hotspots result, and no VCEP or authoritative domain table is available for PRF1. The supplied evidence does not establish that residue 209 lies in a critical, well-established functional domain or mutational hotspot without benign variation; therefore PM1 cannot be determined under the generic rule.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • vcep_materials.json reports no VCEP materials and an empty domain_tables object for PRF1, so no authoritative gene-specific domain list is available.
  • The Cancer Hotspots result for PRF1 Q209 returned no result and states that the variant does not lie in a statistically significant hotspot.
  • No supplied source establishes residue 209 as part of a critical and well-established PRF1 functional domain without benign variation.
Still missing
  • An authoritative PRF1 critical-domain or hotspot source, with residue 209 explicitly included, is needed.
  • Evidence that the relevant domain or hotspot lacks benign variation is needed.
Sources
PM3 ACMG_2015Not assessed: a pathogenic partner is mentioned, but no affected-proband observation or parent/offspring testing establishes trans phase. Details ▾Hide ▴
Reasoning

PRF1-related familial hemophagocytic lymphohistiocytosis is treated here as a recessive disorder under generic ACMG/AMP. The ClinVar submission for NM_001083116.3:c.626A>C (p.Gln209Pro) mentions observation with a pathogenic variant in unrelated affected patients but explicitly does not establish whether the variants were in cis or in trans. No parent or offspring testing, affected-proband-level phase result, or other reliable phasing evidence is documented, so PM3 cannot be assigned.

Rule
For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • ClinVar variation 666080, SCV005325386 evidence signal: the variant was reported with a pathogenic variant in unrelated patients with familial hemophagocytic lymphohistiocytosis, but the submission states that whether the variants occurred on the same or different chromosome was not known.
  • The case evidence contains no parent/offspring testing or other phase determination for NM_001083116.3:c.626A>C (p.Gln209Pro).
Still missing
  • Affected-proband-level evidence identifying the pathogenic partner variant.
  • Parent or offspring testing, or equivalent validated phasing evidence, showing that c.626A>C is in trans with the pathogenic variant.
Sources
PM5 ACMG_2015Not assessed: no different pathogenic missense change at PRF1 residue 209 was supplied as a comparator for p.Gln209Pro. Details ▾Hide ▴
Reasoning

The target is PRF1 p.Gln209Pro. The supplied PM5 candidate record contains no comparator variants and reports zero same-residue candidates; ClinVar evidence concerns the exact target variant and does not establish a different pathogenic missense substitution at residue 209. Therefore the required same-residue pathogenic comparator is not available.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • pm5_candidates.json reports zero total candidates and zero same-residue candidates for PRF1 residue 209, with no comparator variant to evaluate.
  • ClinVar variation 666080 is an exact record for c.626A>C p.Gln209Pro and does not establish a different missense substitution at residue 209.
Still missing
  • A validated pathogenic PRF1 missense variant affecting residue 209 but producing an amino acid other than proline is needed.
Sources
pm5_candidatesclinvar ↗
PM6 ACMG_2015Not assessed: no parental testing or other documented evidence supports assuming that this variant arose de novo. Details ▾Hide ▴
Reasoning

No case-level evidence documents an assumed de novo occurrence of NM_001083116.3:c.626A>C. In particular, neither parental variant testing nor a basis for assuming de novo status is provided. Therefore PM6 cannot be assessed.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The available case evidence contains no parental testing results or case-specific de novo assessment for NM_001083116.3:c.626A>C.
Still missing
  • Parental genotypes are not documented.
  • The basis for assuming de novo status is not documented.
PP1 ACMG_2015Not assessed: no variant-specific affected relatives, co-segregation results, or meioses are documented for this family. Details ▾Hide ▴
Reasoning

No family-level data show NM_001083116.3:c.626A>C co-segregating with disease in affected relatives. The available literature metadata does not provide variant-specific pedigrees, affected relatives, or meioses for this variant. Therefore PP1 cannot be assessed.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
  • The available case evidence includes no family pedigree or variant-specific segregation data; a ClinVar submission signal mentioning PP1 is not sufficient because its underlying family observations are not documented here.
Still missing
  • Affected relatives and their clinical phenotypes are not documented.
  • Variant genotypes for affected and unaffected relatives are not documented.
  • The number of informative meioses is not documented.
  • The available papers lack extracted variant-specific segregation findings.
PP2 ACMG_2015Not assessed: the supplied evidence does not establish both low benign missense variation and a common missense disease mechanism for PRF1. Details ▾Hide ▴
Reasoning

The supplied case evidence supports that PRF1 loss of function is a disease mechanism, but it does not establish both components required for PP2: a low rate of benign missense variation and that missense variants are a common disease mechanism. The available gnomAD record is variant-specific and cannot establish the gene-level missense-rate requirement.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • The case summary states that PRF1 loss of function is a supported germline disease mechanism, but that is not evidence that missense variants are a common disease mechanism.
  • The supplied gnomAD observations are for this individual variant only and do not provide the required gene-level benign-missense rate.
Still missing
  • A gene-level assessment demonstrating a low rate of benign PRF1 missense variation is needed.
  • A gene-level assessment demonstrating that missense variants are a common PRF1 disease mechanism is needed.
BS2 ACMG_2015Not assessed: gnomAD shows zero homozygotes, but no identified healthy adult observation with documented age, health, and relevant zygosity is available. Details ▾Hide ▴
Reasoning

BS2 cannot be assessed from the available evidence. gnomAD reports zero homozygotes for this variant in v2.1 and v4.1, but allele-count data do not document an observed healthy adult individual, the individual's age, clinical status, zygosity in a disease-relevant inheritance model, or whether full penetrance at an early age is expected. Therefore the population databases cannot establish the BS2 healthy-adult observation requirement.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 reports 31/1,613,994 alleles and 0 homozygotes; gnomAD v2.1 reports 3/248,848 alleles and 0 homozygotes.
  • gnomAD allele and homozygote counts do not identify individual adult age, health status, or the clinical context required by BS2.
Still missing
  • A documented healthy adult carrier or homozygote/hemizygote, with age, health status, zygosity, inheritance model, and penetrance context, is required to assess BS2.
Sources
BS3 ACMG_2015Not assessed: no variant-specific validated assay demonstrated normal PRF1 protein function or splicing for p.Gln209Pro. Details ▾Hide ▴
Reasoning

The variant is NM_001083116.3:c.626A>C (PRF1 p.Gln209Pro). The available case evidence does not provide a variant-specific in vitro or in vivo functional result demonstrating preserved protein function or normal splicing, nor does it provide assay controls, biological relevance, or validation and reproducibility data. The cited publications were screened, but the available records do not identify this exact variant as having functional assay data. Therefore, the BS3 requirement for well-established functional evidence showing no damaging effect cannot be adjudicated from the available evidence.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • The case evidence identifies NM_001083116.3:c.626A>C as PRF1 p.Gln209Pro but contains no variant-specific functional assay result showing preserved function or normal splicing.
  • PMID:26450956 was screened by title and case-evidence metadata; the available record concerns flow-cytometric perforin screening but does not document a normal-function result for p.Gln209Pro.
  • PMID:32542393 was screened by abstract and case-evidence metadata; the available record describes a sequencing cohort and does not document a normal-function result for p.Gln209Pro.
  • PMID:28492532 was screened as a general ACMG/AMP criteria-refinement paper and does not provide variant-specific functional evidence.
Still missing
  • Variant-specific functional result showing no damaging effect
  • Protein-function or splicing assay controls
  • Validation, reproducibility, and robustness of the assay
BS4 ACMG_2015Not assessed: no informative affected relatives are documented whose genotypes could demonstrate lack of segregation with disease. Details ▾Hide ▴
Reasoning

No affected family members with documented absence of NM_001083116.3:c.626A>C are identified. Because neither an informative pedigree nor genotype and phenotype results for affected relatives are available, lack of segregation cannot be evaluated and BS4 cannot be assessed.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The available case evidence contains no affected-relative genotype/phenotype comparisons or pedigree information to evaluate non-segregation.
Still missing
  • Informative affected family members are not documented.
  • Genotypes of affected relatives are not documented.
  • Phenotype assessments and possible phenocopies are not documented.
  • The family structure and inheritance context are not documented.
BP1 ACMG_2015Not assessed: loss-of-function disease mechanism is supported, but predominance of truncating PRF1 disease variants is not established. Details ▾Hide ▴
Reasoning

The supplied evidence indicates that PRF1 loss of function is a disease mechanism, but it does not establish that disease-causing PRF1 variants are primarily truncating. The presence of a loss-of-function mechanism alone is insufficient to determine the required variant-spectrum predominance for BP1.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • The case summary supports PRF1 loss of function as a germline disease mechanism, but it does not quantify or establish that disease is caused primarily by truncating variants.
  • The available ClinVar record is an exact missense variant record with conflicting classifications and does not establish the gene-wide disease-variant spectrum.
Still missing
  • A sufficiently characterized PRF1 disease-variant spectrum showing that primarily truncating variants cause disease is needed.
BP2 ACMG_2015Not assessed: a pathogenic partner is mentioned, but cis/trans phase and the fully penetrant dominant context required for BP2 are undocumented. Details ▾Hide ▴
Reasoning

The ClinVar submission mentions observation of NM_001083116.3:c.626A>C (p.Gln209Pro) with a pathogenic variant in unrelated patients, but does not establish cis or trans phase. No cis-phase observation is documented, and the available evidence does not establish the fully penetrant dominant gene/disorder context required for the trans branch of BP2; therefore BP2 cannot be assigned.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • ClinVar variation 666080, SCV005325386 evidence signal: co-occurrence with a pathogenic variant was mentioned, but the submission did not determine whether the variants were in cis or in trans.
  • No cis-phase result or fully penetrant dominant inheritance context is documented in the case evidence.
Still missing
  • Validated phasing evidence showing the two variants are in cis, or evidence establishing a fully penetrant dominant disorder with the variants in trans.
  • Affected-proband and inheritance information sufficient to evaluate the applicable BP2 branch.
Sources
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_001083116.3:c.626A>C in PRF1 is a missense substitution predicted to produce NP_001076585.1:p.(Gln209Pro). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for PRF1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001083116.3:c.626A>C in PRF1 is a missense substitution predicted to produce NP_001076585.1:p.(Gln209Pro). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for PRF1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001083116.3:c.626A>C in PRF1 is a missense substitution predicted to produce NP_001076585.1:p.(Gln209Pro). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for PRF1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001083116.3:c.626A>C in PRF1 is a missense substitution predicted to produce NP_001076585.1:p.(Gln209Pro). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for PRF1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
PRF1
Transcript
NM_001083116.3
Coding (HGVS c.)
NM_001083116.3:c.626A>C
Protein (HGVS p.)
NP_001076585.1:p.(Gln209Pro)
GRCh38
chr10:70599095 T>G
GRCh37
chr10:72358851 T>G
Location and type
Exon 3 · missense
ClinVar
666080

Gene diagram

Every interpreted variant in PRF1, mapped onto the exon structure of NM_001083116.3. Select a row to find it on the plot.

PRF1NM_001083116.3
Fetching transcript structure from UCSC…
gnomAD v4.1 31 / 1,613,994 alleles AF 1.92e-05 · 0 homozygotes · FAF 1.88e-05
gnomAD v2.1 3 / 248,848 alleles AF 1.21e-05 · 0 homozygotes · FAF 2.98e-06
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 1.9e-05 · 31 / 1,613,994 alleles · 0 hom · FAF 1.9e-05
European (non-Finnish)31 / 1,179,942 2.6e-05
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 1.2e-05 · 3 / 248,848 alleles · 0 hom · FAF 3e-06
African/African American1 / 16,174 6.2e-05
European (non-Finnish)2 / 111,476 1.8e-05
0 alternate alleles recorded in 6 other groups: Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.9207e-05; MAF= 0.00192%, 31/1613994 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 2.62725e-05; MAF= 0.00263%, 31/1179942 alleles, homozygotes = 0); grpmax FAF= 1.883e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.20556e-05; MAF= 0.00121%, 3/248848 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 6.18276e-05; MAF= 0.00618%, 1/16174 alleles, homozygotes = 0); grpmax FAF= 2.98e-06.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -2 bp
0.024
SpliceAI acceptor gainat -16 bp
0.050
SpliceAI donor lossat +269 bp
0.000
SpliceAI donor gainat -358 bp
0.000
Pangolin splice lossmagnitude shown
-0.033
Pangolin splice gain
0.071

Other predictors

REVEL
0.420
BayesDel
-0.224

How the predictions were used

PP3 ACMGNot met: the missense REVEL score is 0.42, below the generic supporting PP3 threshold of 0.644. Details ▾Hide ▴
Reasoning

PP3 applies here through the missense path only, so REVEL is the governing predictor and SpliceAI is excluded from this criterion. NM_001083116.3:c.626A>C in PRF1 is a missense variant producing p.(Gln209Pro), and its REVEL score is 0.42. This is below the generic ClinGen SVI supporting PP3 threshold of >= 0.644, so PP3 is not met. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)...Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant....PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001083116.3:c.626A>C, p.(Gln209Pro).
  • Applicable predictor path: missense variants use REVEL only; the SpliceAI score is not evidence for PP3/BP4 in this situation.
  • Local REVEL lookup reports a score of 0.42 for this variant.
  • Generic ClinGen SVI REVEL calibration: PP3 supporting requires >= 0.644 (Pejaver et al. 2022, Am J Hum Genet, PMID:36413997).
  • BayesDel is not used because no generic ACMG-strength calibration is established for PP3/BP4.
Sources
revel
BP4 ACMGNot met: the missense REVEL score is 0.42, above the generic supporting BP4 threshold of 0.29 and therefore gray-zone. Details ▾Hide ▴
Reasoning

BP4 applies here through the missense path only, so REVEL is the governing predictor and SpliceAI is excluded from this criterion. NM_001083116.3:c.626A>C in PRF1 is a missense variant producing p.(Gln209Pro), and its REVEL score is 0.42. The score is above the generic supporting BP4 threshold of <= 0.29 and therefore lies outside the BP4-supporting range; the gray-zone result does not permit substituting the SpliceAI max delta of 0.05. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)...Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant....BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Variant consequence: missense, NM_001083116.3:c.626A>C, p.(Gln209Pro).
  • Applicable predictor path: missense variants use REVEL only; the SpliceAI score is not evidence for PP3/BP4 in this situation.
  • Local REVEL lookup reports a score of 0.42 for this variant, which is above the BP4 supporting cutoff and remains indeterminate for benign computational evidence.
  • Generic ClinGen SVI REVEL calibration: BP4 supporting requires <= 0.29 (Pejaver et al. 2022, Am J Hum Genet, PMID:36413997).
  • SpliceAI max delta is 0.05, but it is not used because this is a missense variant and the governing path is REVEL only.
  • BayesDel is not used because no generic ACMG-strength calibration is established for PP3/BP4.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001083116.3:c.626A>C in PRF1 is a missense substitution predicted to produce NP_001076585.1:p.(Gln209Pro). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for PRF1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.05). REVEL score = 0.42. BayesDel score = -0.223528.

2 paper records listed. 2 cited in the classification.

Cited in the classification

  • Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations.
    Abdalgani M et al. · 2015 Oct 8
    The available case record identifies a paper on flow-cytometric perforin screening for patients with PRF1-related familial hemophagocytic lymphohistiocytosis, but it does not provide an extract showing a functional result for NM_001083116.3:c.626A>C (p.Gln209Pro).
    → PS4 · strong Does not name this variant
    PMID 26450956 ↗
    Source detail
    Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations.

    Location Title in available publication metadata

    Context Flow-cytometric perforin screening study; variant-specific assay details were not available in the retrieved case record.

  • Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders.
    Gadoury-Levesque V et al. · 2020 Jun 23
    The available abstract describes targeted next-generation sequencing of 1,892 patients with suspected genetic hemophagocytic lymphohistiocytosis and reports the distribution of disease-associated variants, but it does not provide a functional assay result for p.Gln209Pro.
    → PS4 · strong Names this variant
    PMID 32542393 ↗
    Source detail
    Samples from 1892 patients submitted for HLH genetic analysis were studied between September 2013 and June 2018 using a targeted next-generation sequencing panel approach.

    Location Abstract in available publication metadata

    Context Large tertiary clinical referral laboratory cohort; targeted next-generation sequencing of 15 HLH-associated genes.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.9207e-05; MAF= 0.00192%, 31/1613994 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 2.62725e-05; MAF= 0.00263%, 31/1179942 alleles, homozygotes = 0); grpmax FAF= 1.883e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.20556e-05; MAF= 0.00121%, 3/248848 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 6.18276e-05; MAF= 0.00618%, 1/16174 alleles, homozygotes = 0); grpmax FAF= 2.98e-06.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (1 clinical laboratory) and as Pathogenic (1 clinical laboratory). (ClinVarID = 666080)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.05). REVEL score = 0.42. BayesDel score = -0.223528.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.